Skip to main content
Full access
Letters
Published Online: 1 April 2012

Dysgeusia Successfully Treated With Sertraline

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Dysgeusia is a qualitative gustatory disturbance relating to a distorted taste perception. Total dysgeusia, an inability to interpret all basic tastes, often occurs with zinc deficiency.1 In addition, taste disturbances have also been reported in patients with major depressive disorder.2 Sertraline, one of selective serotonin reuptake inhibitors (SSRIs) is shown to be effective and well tolerated by elderly outpatients with major depressive disorder.3 Presented here is a case of an elderly patient with mild depression who presented dysgeusia successfully treated with sertraline.

Case Report

A 78-year-old man, who had never experienced depressive symptoms, suddenly noticed peculiar dysgeusia. He described every food as having no taste but was able to discern sweet, salty, sour and bitter tastes. He lost weight because of appetite loss and was referred to the otorhinolaryngologist in our hospital. Serum concentration of zinc was low but the administration of zinc sulfate failed to improve dysgeusia. His dysgeusia persisted for 6 months and was thereafter referred to us. At that time, he also presented severe insomnia and his Hamilton Rating Scale for Depression (Ham-D) and Center for Epidemiologic Studies Depression Scale (CES-D) scores were 14 and 12, respectively, thus suggesting the presence of a mild depression. The administration of sertraline was initiated at a dose of 25 mg/day, and 2 weeks later it was increased to 50 mg/day. About one month after the initiation of sertraline, he described sweet foods as a pleasant sweet taste, while salty, sour and bitter foods remained unpleasant. His taste disturbances and appetite loss ameliorated three months after starting the sertraline treatment and has subsequently been maintained on 100 mg/day of sertraline without any taste disturbance.

Discussion

The most common cause of dysgeusia is the damage of taste cells induced by zinc deficiency,1 in which total dysgeusia occurs. In the present case, dysgeusia did not disappear with the normalization of serum zinc concentration. Anhedonia, loss of interest in and withdrawal from all regular and pleasurable activities including experiences of sensory pleasures (e.g. taste or smell), is a cardinal feature of major depressive disorder. Recently, Dichter et al reported that anhedonia observed in patients with major depressive disorder is not associated with sensory responses to sweet tastes measured by the sweet taste test.4 Thus, the impairment of cognitive function to evaluate pleasurable stimuli might occur in the major depressive disorder. On the other hand, the effect of SSRIs on taste perception could occur at the level of taste receptor cells.5 In healthy volunteers, paroxetine, another SSRI, increases both sweet and bitter sensitivity by reducing taste threshold by 27 and 53%, respectively.5 In the present case, sertraline might improve taste disturbances by enhancing the serotonergic neurotransmission resulting in the reduction of taste threshold. Dysgeusia is one of neglected symptoms of depression.2 Whatever the underlying mechanism, sertraline appears to be an effective treatment for patients suffered from dysgeusia.

References

1.
Markley EJ, Mattes-Kulig DA, Henkin RI: A classification of dysgeusia. J Am Diet Assoc 1983; 83:578–580
2.
Miller SM, Naylor GJ: Unpleasant taste—a neglected symptom in depression. J Affect Disord 1989; 17:291–293
3.
Schneider LS, Nelson JC, Clary CM, et al.: Sertraline Elderly Depression Study Group: An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160:1277–1285
4.
Dichter GS, Smoski MJ, Kampov-Polevoy AB, et al.: Unipolar depression does not moderate responses to the Sweet Taste Test. Depress Anxiety 2010; 27:859–863
5.
Heath TP, Melichar JK, Nutt DJ, et al.: Human taste thresholds are modulated by serotonin and noradrenaline. J Neurosci 2006; 26:12664–12671

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E42
PubMed: 22772699

History

Published online: 1 April 2012
Published in print: Spring 2012

Authors

Details

Yoshito Mizoguchi, M.D.
Shigeto Yamada, M.D.
Department of Neuropsychiatry, Faculty of Medicine, Saga University, Saga, Japan

Notes

Corresponding author: Yoshito Mizoguchi, M.D. Department of Neuropsychiatry, Graduate School of Medical Sciences, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. Phone: +81-952-34-2304 Fax: +81-952-34-2048 e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share